CHNO des Quinze-Vingts   Report issue

Academic/Hospital Phase 2
Founded: Paris France (2011)

Organization Overview

First Clinical Trial
2011
NCT01619189
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts | Centre Hospitalier National d'Ophtalmologie des Quinze Vingts, Paris | Centre Hospitalier National d'Ophtalmologie des Quinze-Vints | Centre National d'Ophtalmologie des Quinze-Vingts | CIC CHNO DES QUINZE VINGTS | Hopital Nationale des Quinze-Vingt, Paris France

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arteritis (Phase 2)

Giant Cell Arteritis (Phase 2)

Ischemia (Phase 2)

Macular Degeneration (Phase 2)

Optic Atrophy, Hereditary, Leber (Phase 2)

Optic Nerve Diseases (Phase 2)

Optic Neuropathy, Ischemic (Phase 2)

Polymyalgia Rheumatica (Phase 2)

Retinal Vein Occlusion (Phase 2)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Syndrome (Phase 2)

Usher Syndromes (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 9